Introduction
============

The global efforts in transcriptome mapping have suggested the pervasive transcriptional potential of human genome and identified numerous non-coding transcripts. Based on the length, the non-coding RNAs can be divided into small non-coding RNAs (\<200 bp) and long non-coding RNAs (lncRNAs) (\> 200bp) [@B1], [@B2].

Reviews on functions of lncRNAs in cancer have been published, describing repeatedly current knowledge on prominent cancer lncRNA candidates. Specific reviews on lncRNAs with regard to urological cancers have also been published [@B3]-[@B6].

LncRNAs may exhibit tissue- or disease-specific expression which can provide potential biomarkers. However, the utility of lncRNA as biomarkers appears to be overstated due to heterogeneous results from different studies. In many cases, initial reports could indeed not be replicated. The story of prostate cancer gene 3 (*PCA3*) is a good illustration of how long and tedious the path to a clinically successful biomarker really is. Thus, a review on the biomarker potential of lncRNAs should be critical and cautious.

This review provides an update on findings of lncRNAs in urological cancer by assessing the literature until March, 2016 from PubMed and discusses the suitability of lncRNAs as diagnostic or prognostics markers in a balanced and critical manner.

Mechanisms of Lncrna Function
=============================

LncRNAs function through a variety of mechanisms (Figure [1](#F1){ref-type="fig"}), e.g. as (i) recruiters regulating gene expression in cis and in trans; (ii) scaffolds that assemble chromatin remodeling machinery at the site of regulation; (iii) decoys that titrate away and prevent the action of effector molecules; (iv) mediators of alternative splicing; (v) precursors for small ncRNAs. Understanding this functional versatility is critical for the clinical exploitation of the lncRNAs.

Locus-Specific Recruiters
=========================

Many lncRNAs are highly enriched in the chromatin fraction where they regulate transcription regulation through the recruitment of chromatin remodeling complexes. Such lncRNAs can alter epigenetic states either in cis or in trans.

Antisense RNA-mediated Cis-Regulation
-------------------------------------

Many lncRNAs overlap protein-coding genes but are transcribed in the antisense orientation. Antisense RNAs are well suited for cis-regulation of their sense counterparts. The locally accumulated antisense RNAs are assumed to recruit chromatin remodeling proteins through either RNA-RNA or DNA-RNA recognition rules and trigger heterochromatin formation for gene silencing. A growing list of the validated sense-antisense pairs has been implicated in urologic cancer.

One typical example is the action of antisense ncRNA in the INK4 locus (*ANRIL*). *ANRIL* mediates silencing of a cluster of tumor suppressor genes, including its sense partner *p15/CDKN2B* through SUZ12 (a PRC2 component) and the *p16/CDKN2A*and *p14/ARF* locus via CBX7 (a PRC1 subunit).

RASSF1 antisense RNA 1 (*RASSF1-AS1*) is a tumor suppressor involved in cell cycle and apoptosis in prostate cancer [@B7]. *RASSF1-AS1* forms an RNA-DNA hybrid at the *RASSF1A* promoter and recruits PRC2 which specifically represses *RASSF1A* transcription.

C Terminal Binding Protein 1 Antisense (*CTBP1-AS*) is a key antisense ncRNA upregulated in prostate cancer and negatively correlated with its sense gene *CTBP1* [@B8]. *CTBP1-AS* recruits transcriptional repressor PSF and histone deacetylases to *CTBP1* promoters and represses *CTBP1* expression in cis. *CTBP1-AS* also inhibits tumor suppressors in trans via the PSF-dependent mechanism thus facilitating prostate cancer initiation and progression.

Another example of the RNA guiding mechanism could be seen by the action of the *ncRNACCND1* expressed at the 5\'-regulatory region of the cyclin D1 (*CCND1*) gene [@B9]. *ncRNACCND1* is expressed upon DNA damage and recruits the RNA binding protein TLS that represses CBP/p300 activities on *CCND1* in cis, causing gene-specific inhibition.

Other antisense lncRNAs were found to be inversely related to their antisense partners in urological cancer, e.g. *TRPM2-AS*, *CBR3-AS1*, 5\' and 3\'*aHIF-1α*, *ZEB2NAT* and *MDC1-AS*. But the precise mechanisms underlying the regulation of sense transcript have yet to be deciphered. *TRPM2-AS* [@B10] is consistently upregulated in prostate cancer and inversely related to its antisense transcript *TRPM2*, dictated by methylation degree of the CpG island. *TRPM2* silencing leads to decreased susceptibility to cell apoptosis and necrosis. CBR3 antisense RNA 1 (*CBR3-AS*1) is significantly upregulated in primary prostate tumors and PCa cells [@B24]. Silencing of *CBR3-AS1* downregulates AR, inhibits cell growth, and increases apoptosis in both androgen-dependent and independent LNCaP cells. Cui et al. [@B11] suggested a reciprocal regulation of *CBR3-AS1* and AR in a positive feedback loop in prostate tumorigenesis. While others characterized *5\'aHIF-1α* and *3\'aHIF-1α*, two antisense transcripts at the 5\' and 3\' end of the human hypoxia-inducible factor-1α (*HIF-1α*) gene [@B12] respectively in kidney tumor specimen. *5\'aHIF-1α* and *3\'aHIF-1α* are involved in different regulation mechanisms and are activated under different environmental stress and histological cell types. *3\'aHIF-1α* binds to the 3\'UTR of *HIF-1α* and down-regulates *HIF-1α* translation. Moreover, *3\'aHIF-1α* is overexpressed specifically in non-papillary kidney cancer and could discriminate between papillary and nonpapillary renal cell carcinoma [@B13]. *5\'aHIF-1α* is involved in membrane transport and mediates the *HIF-1α* pathway. Recently, Zhuang et al. [@B14] reported a novel antisense lncRNA *ZEB2NAT* of *ZEB2* that enhances the invasion of UBC cells through the TGFβ1-*ZEB2NAT*-*ZEB2* axis. Xue et al. [@B15] identified antisense lncRNA *MDC1-AS* that upregulates the expression of tumor-suppressing *MDC1* in bladder cancer.

Cis-silencers in Genomic Imprinting
-----------------------------------

Several cis-regulatory lncRNAs are also functionally involved in genomic imprinting, which is an epigenetic event whereby one parental allele is preferentially silenced to maintain the allele-specific expression. Disturbed imprinting in *XIST*, *CDKN1C/KCNQ*, *H19/IGF2* and *DLK1/MEG3* loci is commonly observed in urologic cancers.

X-inactive specific transcript (*XIST*) is a 19 kb long lncRNA expressed exclusively from the inactive X chromosome. It mediates X chromosome inactivation in female mammalian cells to balance the X-chromosome genes dosage between the male and female. *XIST* recruits PRC2 to the polycomb group transcription factor YY1, which can load the *XIST*-PRC2 complex onto the Xic and initiate H3K27me3 throughout the Xi. *XIST* promoter is hypomethylated in prostate cancer tissues and cell lines [@B16], [@B17].

An additional example is the *KCNQ1* opposite strand transcript 1 (*KCNQ1OT1*) in the *KCNQ1* imprinted gene cluster. *KCNQ1OT1* is paternally expressed and bidirectionally silences cis-linked imprinted genes of the centromeric domain. *KCNQ1OT1* binds both PRC2 and G9a to promote two different repressive histone marks H3K27me3 and H3K9me3, thereby mediating the silencing of the flanking genes. On the maternal chromosome where *ICR2* promoter is methylated, *KCNQ1OT1* is silenced and the imprinted genes are transcribed. Altered expression and functional implication of *KCNQ1OT* have been investigated in bladder cancer [@B18], prostate cancer [@B19], Beckwith-Wiedemann syndrome (BWS) [@B20], [@B21], Wilms\' tumors [@B22] as a consequence of disturbed imprinting.

Defective imprinting in *H19/IGF2* locus is also a common event in bladder cancer and Wilms tumors. *H19/IGF2* harbors conversely imprinted *IGF2* and *H19* expressed from the paternal and the maternal alleles respectively. In bladder cancer, the *H19* promoter is paternally hypomethylated [@B23], causing biallelic expression of *H19* and silencing of *IGF2*. The induced *H19* promotes cell growth by regulating *ID2* expression [@B24] and also contributes to metastasis by associating with enhancer of zeste homolog 2 (EZH2) and inhibiting E-cadherin transcription [@B25]. Unlike the situation in bladder cancer, Wilms tumor is linked to a gain in methylation on the maternal allele [@B26], [@B27]. Biallelic methylation of the *H19* promoter silences *H19* and causes biallelic expression of *IGF2*, thereby stimulating cell growth. In BWS, the epigenetic *H19* silencing increases the risk of developing childhood tumors [@B21].

*DLK1/MEG3* locus is structurally and epigenetically similar to the *IGF2/H19* domain. The locus contains the paternally imprinted non-coding *MEG3* and the maternally imprinted *DLK1*. *DLK1* and *MEG3* are prevalently downregulated in prostate cancer [@B19], bladder cancer [@B28], [@B29] and primary renal cell carcinoma (RCC) tissues [@B30] caused by the epigenetic silencing across the 14q32 imprinted gene cluster.

lncRNA Action in Trans
----------------------

Despite prominent examples of lncRNA action in cis, lncRNAs also affect a large number of genes in trans.

The HOX transcript antisense RNA (*HOTAIR*) guides both histone modification complexes PRC2 and LSD1 to their target genes genome-wide and mediates epigenetic silencing. *HOTAIR* expression is elevated in castration resistant prostate cancer [@B31] and renal carcinoma cell lines [@B32].

*linc-UBC1* also functions as recruiter in trans. *linc-UBC1* is overexpressed in primary bladder cancer. It recruits PRC2 complex and increases H3K27Me3 in the promoter of *CCND2* and *HOXA5* and depressed their expression. Knockdown of *linc-UBC1* inhibits proliferation and compromises invasiveness, cell motility and metastasis.

Molecular Scaffolds
===================

Emerging evidence indicates that lncRNAs serve as molecular scaffolds that mediate chromosomal looping between distal enhancer and promoter.

Yang et al. [@B33] suggested that PCa non-coding RNA 1 (*PRNCR1*) and prostate cancer 2 gene expression marker 1 (*PCGEM1*) mediate chromosomal looping to regulate androgen receptor (AR) dependent transcription. *PRNCR1* interacts with the AR and recruits DOT1-like histone H3K79 methyltransferase (DOT1L), which in turn methylates AR. The activated AR binds to *PCGEM1*, which recruits pygopus family PHD finger 2 (PYGO2). PYGO2 recognizes H3K4me3 at gene promoters. Subsequently, a complete loop from a distal upstream enhancer to the promoter is established leading to the activation of the androgen-responsive genes.

However, the role of *PRNCR1* and *PCGEM1* in AR activation was challenged by later researches. Prensner et al. [@B34] observed no evidence for their interaction with the AR. Parolia et al. [@B35] showed that *PCGEM1* is uniformly distributed in PCa cell nucleus and cytoplasm, and remains unaltered upon AR activation. Hung et al. [@B36] found that *PCGEM1* promotes proliferation not via AR activation, but through *c-Myc* activation. Therefore, the role of *PCGEM1* and *PRNCR1* in castration resistant prostate cancer (CRPC) remains uncertain.

A recent study [@B37] indicated two additional lncRNAs *MALAT1* and Taurine upregulated gene 1 (*TUG1*) serving as sub-nuclear molecular scaffolds that mediate growth control gene relocation between nuclear structures. *TUG1* is upregulated in bladder urothelial carcinoma. It selectively guides the methylated Pc2 on growth control gene promoters to the co-repressor complexes in PcG bodies for transcription repression. *MALAT1* interacts with unmethylated Pc2 in the activation environment of the ICGs for transcription activation.

Target Decoy or Mimicry
=======================

Another means by which lncRNAs regulate transcription is to act as decoys. In this archetype, lncRNAs sequester biomolecules away from natural target and prevent them from fulfilling functions. This kind of lncRNAs always antagonize transcription regulators, so knockdown of these lncRNAs may lead to gain-of-function of its targets [@B38].

Decoy at Transcriptional Level
------------------------------

One particular type of lncRNA decoy involves proteins. lncRNA can bind to transcription-factors that would otherwise bind to the DNA promoters and thereby inhibit gene transcription.

The second chromosome locus associated with prostate-1 (*SCHLAP1*) is a protein-interacting lncRNA implicated in tumor invasion and metastasis and upregulated in aggressive PCa [@B39]. Mechanistically, *SCHLAP1*co-immunoprecipitates with SNF5, a core unit of the SWI/SNF complex and impairs the SWI/SNF-mediated epigenetic regulation. SWI/SNF complex is a well-documented chromatin regulator with tumor suppressor function. This complex remodels the chromatin and physically moves nucleosomes at gene promoters to control transcription.

In contrast to *SCHLAP1* which is pro-survival, Growth-Arrest Specific 5 (*GAS5*) is a tumor suppressor with a pro-apoptotic role in prostate cancer. *GAS5* has a stem-loop structure in its sequence that mimics the glucocorticoid responsive gene. *GAS5* binds to glucocorticoid receptors and prevents its genomic binding. This results in the suppression of GR responsive genes such as anti-apoptotic *cIAP2* [@B40] and ultimately induces growth arrest [@B41]. *GAS5* can also inhibit transcriptional stimulation of progesterone receptor and androgen receptor in a similar fashion. Since androgen receptor is critical in prostate cancer cells survival, down regulation by *GAS5* may inhibit pro-survival signaling via the androgen receptor pathway.

Decoy at Translational Level
----------------------------

LncRNA decoys not only proteins, but also microRNAs. In this context, lncRNAs act as competing endogenous RNAs (ceRNAs) that sponge microRNAs to interfere with their function (Figure [2](#F2){ref-type="fig"}).

A prominent example is the *PTENP1*, pseudogene of the tumor suppressor *PTEN* [@B42], [@B43]. *PTEN* and *PTENP1* share multiple miRNA target sites, therefore *PTENP1* competes for the same set of regulatory miRNAs that normally targeted *PTEN* to modulate *PTEN* expression [@B44]. *PTEN* is commonly lost in advanced PCa [@B45] and clear cell renal cell carcinoma (ccRCC) [@B44]. The restoration of *PTEN* inhibits tumor cell proliferation [@B46]. The prostate cancer associated transcript 1 (*PCAT1*) is another lncRNA as miRNA antagonizer. *PCAT1* is the top-ranked, upregulated lncRNA in prostate cancer tissues. *PCAT1* disrupts miR-34a mediated down-regulation of *cMyc* [@B34] and promotes proliferation. Further, *PCAT1* downregulates the tumor suppressor gene *BRCA2* [@B47], similar to microRNA mediated mRNA degradation. *MALAT1* also serve as a ceRNA through interfering with miR-200s and increases *ZEB2* expression in ccRCC [@B48]. Urothelial carcinoma-associated 1 (*UCA1*) acts as a nature decoy that blocks miR-16 to inhibit ROS formation, thus promoting tumorigenesis in bladder cancer [@B49].

Mediators of Alternative Splicing
=================================

Recently lncRNAs have been shown to act at a post-transcriptional level by regulating alternative splicing of pre-mRNAs.

*MALAT1* is enriched in nuclear speckles, a sub-nuclear domain that is enriched with various pre-mRNA splicing factors including Serine-Arginine (SR) protein. *MALAT1* harbors a large number of SR protein binding sites. It modulates the phosphorylation of Serine-Arginine (SR) splicing factors and mediates their distribution [@B50] in the nuclear speckles, thereby controlling the localization of splicing factors at active transcription sites. Besides SR, *MALAT1* also interacts with other pre-mRNA splicing factors, e.g. PRP6 and TDP-43. *MALAT1* loss-of-function alters alternative splicing pattern of pre-mRNAs such as tissue factors and endoglin which are important in cancer biology.

Precursors of Small NcRNAs
==========================

LncRNAs can function as primary precursors for other small ncRNAs deregulated in cancer. It is estimated that at least 4% of lncRNAs host small ncRNAs. For example, *H19* hosts miR-675 in first exon. miR-675 is a tumor suppressor involved in the regulation of developmental genes [@B51]. It inhibits cell proliferation in response to stress or oncogenic signals [@B52].

*GAS5* encodes 10 different small nucleolar RNAs (snoRNAs) in its introns [@B53]. Interestingly, only a subset *GAS5*-encoded snoRNAs are upregulated in progressing PCa [@B54], suggesting that RNA products derived from the same precursor transcript could function through separate mechanisms at post-transcriptional levels.

Clinical Utility of Lncrnas in Urological Cancer Management
===========================================================

Many lncRNAs are expressed in a tissue or cancer specific manner. They are often stable in biological fluids and could be easily detected using qRT-PCR amplification. The specificity and stability of lncRNAs have prompted efforts to evaluate their potential as biomarkers for diagnosis, prognosis, therapy response and therapeutic targets. A list of putative lncRNA biomarkers is summarized in Table [1](#T1){ref-type="table"}.

Risk Prediction
===============

Recently several lncRNAs transcribed from cancer risk loci have been identified. 8q24 gene desert region, for example, harbors several lncRNA genes, e.g. PCAT1 and *PRNCR1*. 8q24 is a key prostate cancer predisposition locus associated with PCa susceptibility. GWAS have discovered within the lncRNAs multiple prostate cancer-associated SNPs for risk prediction. rs378854 in 8q24 region is associated with expression of oncogenic lncRNA *PVT1* in PCa [@B55]. A further lncRNA at the 8q24 region is *PRNCR1* [@B56] transcribed between rs1456315 and rs7463708. It is most significantly related to PCa susceptibility in the Japanese. SNPs in the H19 gene are also associated with the risk of bladder cancer [@B57]. rs2839698TC and rs2107425CT in H19 significantly reduce risk of non-muscle-invasive bladder cancer. rs16834898 and rs6434568 in *PCGEM1* [@B58] indicate a lower PCa risk with Chinese population. However, how these variants affect cancer susceptibility remains to be elucidated.

Markers in Screening and Diagnosis
==================================

Early diagnosis of primary and recurrent cancers followed by timely treatment will significantly decrease mortality. The most common screening test for prostate cancer early detection to date is serum PSA screening. However, the use of PSA lacks specificity and fails to discriminate aggressive tumors from indolent cancers, leading to unnecessary biopsies and overtreatment. Thus there is a continued need for more sensitive and specific biomarkers for prostate cancer early detection that supplement PSA.

Numerous efforts have been applied to transcriptome-wide study of urological cancer and found numerous urological cancer associated lncRNAs. The most promising among these is the *PCA3*. *PCA3* is specifically overexpressed in malignant prostate tissue and absent in indolent prostate conditions or cancers of non-prostate origin. *PCA3* has demonstrated a superior specificity and accuracy to serum PSA. Moreover, *PCA3* is detectable in post-DRE urine samples in urine and urine sediments, therefore enabling noninvasive diagnose. For this reason, *PCA3* has been translated into the clinical setting. A *PCA3* assay PROGENSA® has been approved by the FDA as a diagnostic method to aid in the decision of repeat prostate biopsies [@B59].

Despite the improved specificity, the lower sensitivity of *PCA3* renders it insufficient as a standalone biomarker. However, the inclusion of *PCA3* can improve the diagnostic accuracy of other clinical variables. The combination of urinary *PCA3* and *TMPRSS2:ERG* is currently being addressed in two independent multi-center trials [@B60], [@B61]. A multiplex marker panel consisting of *PCA3*, PSA, *TMPRSS2:*ERG, sarcosine and annexin A3 also showed improved diagnostic accuracy for PCa [@B62]. Combining *PCA3* scores with the Prostate Health Index (Phi) improves specificity in prostate cancer diagnosis than single marker alone [@B63].

In addition to *PCA3*, several other urine biomarkers were under investigation for the detection of PCa. Wang et al. [@B64] observed that urinary *MALAT1* score outperforms the conventional %free PSA in PSA grey zone cohorts (4-10 ng/mL). *MALAT1* could detect more cancer cases and save avoidable and repeated biopsies. The exosomal lincRNA-p21 in urine is diagnostically superior to *PCA3* in distinguishing PCa from benign prostatic hyperplasia (BPH) [@B65]. lincRNA-p21 is a tumor suppressor stimulated by the p53 protein. Once transcribed, lincRNA-p21 binds to the hnRNP-K complex and suppresses expression of the genes regulated by p53. LncRNA FR0348383 [@B66] is upregulated in PCa compared with matched benign tissues. FR0348383 transcript in post-DRE urine has diagnostic value for patient cohorts especially in the PSA grey zone. The application of FR0348383 score could avoid 52% unnecessary biopsies without missing high grade PCa.

Besides urine, diagnostic value of lncRNAs in circulating blood was also evaluated. For example, a *MALAT1* derived fragment, *MD-miniRNA* is differentially expressed in the serum and plasma of PCA patients [@B67], [@B68]. *MD-miniRNA* can distinguish positive prostate biopsies from negative at AUC of 0.841. Compared with PSA, *MD-miniRNA* has better specificity but lower sensitivity for PCa detection. However, the sensitivity of *MD-miniRNA* increases in higher grade tumor samples, which suggest that *MD-miniRNA* may selectively detect aggressive PCa patients. Combined MD-miniRNA and PSA could improve diagnostic sensitivity and specificity. The 5\' region of the *XIST* gene is commonly less-methylated in PCa irrespective of *XIST* expression [@B16]. Identification of a *XIST* hypomethylated fragment in serum may have tumor diagnostic potential for PCa [@B17].

*UCA1* is a well-documented oncogene in bladder cancer which promotes cancer cell growth, invasion and drug resistance [@B69]-[@B71]. Since its first description in 2006 [@B72], many studies have confirmed UCA1 to be specific and sensitive marker for bladder cancer diagnostic or follow-up [@B69]-[@B75]. *UCA1* is especially sensitive in diagnosis of superficial high grade (G2-G3) TCC cases [@B74], [@B75].

Functionally, *UCA1* may exert pro-tumor activity by activating PI3-K signaling pathway [@B70] and Akt signaling pathway [@B70], [@B76]. More recent studies [@B77] put forward that *UCA1* promotes cell growth by downregulating the cell cycle inhibitor p21 via BRG1. *UCA1* is upregulated in bladder cancer cells under hypoxic conditions induced by transcription factor Ets-2 [@B76], CCAAT/enhancer binding protein α (C/EBPα) [@B78] and hypoxia-inducible factor-1α (HIF-1α) [@B79]. The correlation between these molecules under hypoxic conditions remains unclear. *UCA1* is also involved in glucose metabolism in bladder cancer [@B80].

The variant transcript of *UCA1*, *UCA1a* (*CUDR*) also plays a role in bladder cancer progression. Upregulated *UCA1* and *UCA1a* have been shown to enhance resistance to cisplatin in bladder cancer cells [@B71], [@B81], suggesting their role in chemoresistance [@B71].

However, many claims above are based on single reports with small cohorts for which replication studies are mostly lacking. According to a recent report [@B82], the diagnostic value of *UCA1* in bladder cancer is lower than previously reported and its role in the follow-up of recurring tumors is limited. Thus *UCA1* is currently not recommended as standard diagnostic tools in routine urology. *UCA1* can be used only to complement cystoscopy and cytology in the early diagnosis when a primary bladder cancer is suspected.

In addition to *UCA1*, the differential expression pattern of several other lncRNAs has been reported in bladder cancer. *PCAT-1* [@B83] and *H19* [@B24], [@B84] were up-regulated in bladder cancer compared with normal controls. On the other hand, *MEG3* expression is decreased in bladder cancer [@B28]. SncmtRNA and the ASncmtRNAs in urine can detect tumor cells with different grades, and were suggested as a non-invasive diagnostic tool [@B85].

For renal cancer, there is still no reliable biomarker available for daily practice despite numerous efforts. The study of lncRNAs is limited to a few samples that were analyzed by microarrays. Five recent studies investigated the lncRNA expression profile of RCC tissues using microarray technologies. However, the samples sizes are small (n=6 [@B86]; n = 4 [@B87]; n = 6 [@B88]; n = 11 [@B89]; n=15 [@B90]) and lack validation cohort, thereby limiting the value of the studies. Nevertheless, it is obvious that unique lncRNA expression profiles exist in RCC. In accordance with prostate and bladder cancer, *MALAT1* is also overexpressed in RCC than benign renal tissue or cell lines [@B48], [@B91]. *MALAT1* silencing inhibits RCC cell proliferation and promotes apoptosis. Hirata et al. [@B92] found that *MALAT1* is transcriptionally activated by c-Fos downstream of the VHL pathway and interacts with Polycomb protein EZH2 to induce epithelial-to-mesenchymal transition (EMT).

Marker for Prognosis
====================

LncRNAs are also strong predictors of tumor recurrence and patient outcome. *H19* has been advocated as a potential prognostic biomarker for early recurrence in bladder cancer. Hochberg et al [@B93] first reported altered expression of *H19* in bladder cancer. *H19* upregulation is related to an increased risk of biochemical recurrence and shorter metastasis-free survival [@B94]. *linc-UBC1* overexpression is a negative prognostic marker for lymph node metastasis in bladder cancer [@B95].

Upregulation of *HOTAIR* may be closely associated with recurrent and poor prognosis of bladder cancer. *HOTAIR* upregulation associates with increased risk of recurrence in stage Ta/T1 bladder cancer [@B96] and affects invasiveness and differentiation state of urothelial cancer cells in a cell type specific manner. Upregulation of *HOTAIR* is also correlated with histological grades and overall survival in bladder transitional cell carcinoma (TCC) and inhibits chemosensitivity to doxorubicin [@B97]. Elevated *SPRY4-IT1* is strongly correlated with aggressive clinicopatholigcal features and poor prognosis in bladder cancer and provides an unfavorable prognostic factor [@B98]. Upregulation of *MALAT1* in bladder cancer corresponds to the tumor grade and metastatic stage [@B81], [@B99]-[@B101]. Experiment showed that *MALAT1* induces EMT to promote bladder cancer cell migration by associating with suz12 [@B102] and activating Wnt signaling [@B100].

In PCa, high *SChLAP1* expression is correlated with biochemical recurrence, clinical progression and mortality. It significantly predicts metastatic progression in high-risk PCa patients who had undergone radical prostatectomy and lethal mCRPC [@B39], [@B103]. Recently an RNA *in situ* hybridization (ISH) assay for *SChLAP1* was developed for the detection of aggressive prostate cancers [@B104].

*PCGEM1* and *PRNCR1* [@B33] were previously identified to be highly overexpressed in aggressive PCa. While *PCGEM1* is confirmed by later studies to be associated with prostate cancer, *PRNCR1* does not exhibit convincing upregulated expression [@B34], [@B35]. Prensner et al. [@B34] contradicted the prognostic value of *PRNCR1* in aggressive PCa by analyzing a large cohort of high-risk prostate cancer patients. They claimed that *PRNCR1* does not demonstrate a convincing association with poor patient outcomes.

Several studies have reported a significant correlation between *PCA3* score and prognostic parameters. However, the prognostic value of *PCA3* is controversial. Other independent studies [@B105], [@B106] found no significant correlation between the *PCA3* score and clinicopathologic variables.

*HOTAIR* is overexpressed in CRPC cell lines [@B31], tissues [@B107], and after androgen deprivation therapies. Further study demonstrates that the *HOTAIR* directly binds to AR to protect it from ubiquitin-mediated degradation, and thus drives androgen-independent AR activation and promotes CRPC. *GAS5* transcript level is significantly lower in metastatic prostate cell lines compared with normal prostates. Down-regulation of *GAS5* has been found to mediate the progression of CRPC. *PCAT1* is specifically upregulated in high-grade PCa, independent of chromosome 8q24 amplification, and has been implicated as a prognostic biomarker for prostate cancer metastasis and poor overall survival [@B108]. The upregulation of *TRPM2-AS* associates with poor clinical outcome and has been characterized as a high-risk PCa marker [@B109]. *PCAT18* is highly up-regulated in metastatic PCa, and is able to discriminate between localized PCa and metastatic CRPC [@B110]. *PCAT5* was also reported as a CRPC-specific biomarker [@B111]. Linc00963 is differentially expressed in the androgen-independent and metastatic PCa cell line and is responsible for the androgen-independence transition [@B112]. Overexpression of *MALAT1* in PCa tissues is related to high Gleason score, late tumor stage and CRPC. *In vitro MALAT1* silencing inhibits metastasis of CRPC cancer cells and leads to cell cycle arrest. In vivo knock-out of *MALAT1* inhibits growth of tumor xenografts [@B113], [@B114]. *MALAT1* associates with the N-terminal of EZH2 through 3′ end and enhances EZH2-mediated migration and invasion in CRPC cell lines. Knockdown of *MALAT1* impairs EZH2 recruitment to its target loci and represses oncogenetic activity of EZH2 [@B115].

Du et al. [@B116] reanalyzed array-based PCa expression profiles and identified 2 metastases relevant *PCAN-R1* and *PCAN-R2* as potential drivers of cancer progression. Recently, Malik [@B117] identified low *PCAT29* expression correlated with poor prognostic outcomes.

For renal cancer, several independent indicators of clinical outcome have been identified in patients with ccRCC. *SPRY4-IT1* is significantly correlated with advanced clinical stage, lymphnode metastasis and poorer prognosis in ccRCC [@B118]. ccRCC patients with higher *H19* level have more advanced clinical stage and worse overall survival [@B119]. Decreased expression of *NBAT-1* [@B120] is associated with the progression and poor prognosis of ccRCC. Upregulated *RCCRT1* is correlated with tumor stage, histological grade and lymph node metastasis [@B121]. Recently, Malouf et al. [@B122] established a molecular subclass of ccRCC through lncRNA-based clustering and identified cluster C2 to associate with aggressiveness and poor overall survival.

LncRNA-Based Therapy
====================

Anti-cancer strategies based upon lncRNA biology are rapidly emerging. The therapeutic concepts could be either to suppress the oncogene expression or to activate tumor-suppressive lncRNAs.

LncRNA Targeting Strategy
-------------------------

Direct targeting of oncogenic lncRNAs is an attractive strategy for treatment of cancer. A straightforward method is to interfere with RNA expression via antisense technologies. RNAi-mediated gene silencing has recently gained momentum as a treatment modality. Many studies have used RNAi to knockdown spliced lncRNAs. However, RNAi activity is restricted to the cytoplasm and cannot be deployed against a nuclear localized lncRNA.

Other possible lncRNA targeting agents are catalytic nucleic acids (CNAs) such as ribozymes and DNAzymes, which can also bind and cleave lncRNA targets and repress their expression.

An alternative approach would target lncRNA interactions and silence their function. This can be achieved by the use of small molecule inhibitors that block the binding site of their protein partners. Disruption of these molecular interactions compromises the repression of the tumor suppressors and reactivates their function. For example, using small molecular inhibitors of PRC2 to block its interaction with *ANRIL* would be a promising therapeutic strategy.

Targeted Gene Therapy
---------------------

The tumor-specific expression of lncRNA has prompted investigation into its utility in targeted anticancer therapy. One typical example is the use of *H19* regulatory sequences for the treatment of bladder cancer. The BC-819 DNA plasmid, which contains diphtheria toxin controlled under the *H19* promoter, has been designed to treat target cells with overexpressed *H19* [@B123]. When BC-819 enters a cancerous cell, the Diphtheria Toxin A (DTA) chain is synthesized under the regulation of *H19*. This allows precise targeting of tumors without excessive harm to healthy tissue. A multicenter trial of intravesical BC-819/PEI is ongoing in patients with superficial TCC [@B124]. A pivotal (Phase III) bladder cancer clinical trial has commenced in 2015.

A similar vector *H19*-DTA-*P4*-DTA [@B125] is also under consideration for bladder cancer therapy. *H19*-DTA-*P4*-DTA expresses the DTA fragment under the control of two separate promoters from *H19* and *IGF2-P4*. The vector exhibits increased anti-tumor activity than the single promoter vectors.

Tumor-Suppressive LncRNAs
-------------------------

Alternatively, one can also manipulate the expression of tumor-suppressive lncRNAs in anticancer therapy. One example is the protein decoy *GAS5*. Its downregulation was described in prostate cancer cell lines [@B41], RCC [@B126] and bladder cancer [@B127]. *GAS5* expression inhibits androgen receptor signaling, promotes growth arrest and apoptosis [@B41]. Therefore, upregulation of *GAS5* could provide a possible treatment. Based on the observation that mTOR expression is inversely correlated with *GAS5* in PCa cell lines, Yacqub et al. [@B128] examined mTOR inhibition as a strategy to enhance *GAS5* levels in several prostate cancer cell lines.

Lncrna: Current Challenges and Future Directions
================================================

The ever-growing number of lncRNA-based marker candidates stands in sharp contrast to the lack of reliable biomarkers for urological cancer. The biggest challenge is the limited validity. The candidates generated by different labs are non-overlapping or even contradictory [@B129], [@B130]. As discussed earlier, the prognostic value of *PCA3* is controversial [@B34]. The prognostic value of *PRNCR1* in aggressive PCa remains uncertain. It remains to be proven whether *UCA1* is a suitable diagnostic urinary biomarker in bladder cancer. Aberrant expression of individual lncRNAs in RCC by small-scaled studies, i.e. *GAS5* [@B122], [@B126], *aHIF* [@B12], *MALAT1* [@B122] could not be confirmed.

Most current studies aim to identify single molecules as biomarkers, but one size does not fit all. These studies ignore the dynamic molecular interactions and fail to address the heterogeneity of cancer. There is an obvious need to extend the biomarker discovery from single molecules to the functional modules, pathways and the networks. Some systematic studies of lncRNA markers have proliferated recently. As an example, our colleagues [@B131] have constructed a mRNA-lincRNA coexpression network in PCa using RNA-Seq expression data and characterized PCa-associated lincRNA modules as putative biomarkers.

This inter-laboratory inconsistency stems largely from the intrinsic features of cancer. First, the development of cancer is systems-oriented, involving the crosstalk between multiple biological components. Also the cancer is highly heterogeneous, not only between patients, but also within the same individual [@B132]. Most current studies however, aim to identify single molecules as biomarkers, but one size does not fit all. These studies ignore the dynamic molecular interactions and fail to address the heterogeneity of cancer.

There is an obvious need to extend the biomarker discovery from single molecules to the functional modules, pathways and the networks. Some systematic studies of lncRNA markers have proliferated recently. As an example, our colleagues [@B131] have constructed a mRNA-lincRNA coexpression network in PCa using RNA-Seq expression data and characterized PCa-associated lincRNA modules as putative biomarkers.

An additional bias lies in the deficiencies in the population under analysis. The current lncRNA marker candidates are mostly based on discovery-driven approaches that frequently use small sample sizes. This type of analysis is prone to statistical overfitting of high-dimensional data, producing the "p \>\> n" paradigm. Thus, the potential lncRNA markers have yet to be prospectively validated in standardized, well-controlled clinical trials across large numbers of patients. Thus, the diagnostic and therapeutic benefits of many potential lncRNA markers have yet to be prospectively validated in standardized, well-controlled clinical trials across large numbers of patients.

Many more important questions remain to be addressed.

In most cases lncRNA function is not fully understood. It is also not clear whether deregulated lncRNAs are drivers in the disease etiology or they are merely a consequence of the disease. Although aberrant expression of lncRNAs argues in favor of functional significance, but most publication have not described a direct association or causal role for lncRNAs in cancer, therefore its functional role in urological biology is largely unknown.

Assigning functions to lncRNAs may seem like a daunting task. For most lncRNAs, function is solely predicted by bioinformatic tools without any mechanistic understanding and experimental validation. The guilt by association analysis [@B133] has also been used to infer the function of an lncRNA based on their expression correlations with neighboring protein-coding genes with known functions. However, direct experimental test is still important to understand the lncRNA function. The classical experimental strategy would involve the depletion of lncRNA and assessment of the effects on gene expression and tumor-relevant phenotypes. Identification of protein interaction partners is also informative to decipher lncRNA mechanisms at the molecular level. A direct way would be the RNA affinity purification, or RIP-Seq to identify lncRNA-interacting proteins. Two methods, called chromatin isolation with RNA purification (ChIRP) [@B134] and capture analysis of RNA targets (CHART) [@B135], represent complementary approaches to study RNA-chromatin interactions. ChIRP and CHART have uncovered thousands of *PCGEM1* occupancy sites. These methods will help to create an experimentally validated interactome of lncRNAs.

Unraveling the function of lncRNAs is more difficult than miRNA. The difficulties come from the relatively low sequence conservation of lncRNAs. However, the main functionality of lncRNAs may reside in its secondary structure motifs imperative for specific interaction. This is demonstrated by the double stem-loop structure of *HOTAIR* for PRC2 binding and the structure of *MEG3* critical for its tumor suppressor functionality [@B84]. It will be highly informative to understand the sequence motives and functionally active RNA domains that govern lncRNA functionality.

The lncRNA-based therapeutics also has many important questions to be addressed. Targeting lncRNAs with small-interfering RNAs is not trivial due to the large transcripts size and the extensive secondary structures in lncRNAs.

In addition, the development of robust delivery system, optimization of dosage regimes and amelioration of off-target effects require intensive investigation in the future.

Conclusions
===========

LncRNA is shedding light on the understanding of the urological malignancies. Their potential utility in cancer biology and therapy can be tremendous. We remain cautiously optimistic that when the limitations described above are overcome, lncRNAs may be used as promising markers or therapeutic targets to benefit patients.
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ANRIL

:   antisense ncRNA in the INK4 Locus

CAN

:   catalytic nucleic acid

CBR3

:   Carbonyl Reductase 3

CBR3-AS1

:   CBR3 antisense RNA 1

CBX7

:   chromobox homolog 7

CCND1

:   cyclin D1

ccRCC

:   clear cell renal cell carcinoma

CDKN1C

:   Cyclin-dependent kinase inhibitor 1C

CHART

:   capture analysis of RNA targets

ChIRP

:   chromatin isolation with RNA purification

cIAP2

:   cellular inhibitor of apoptosis 2

CRPC

:   castration resistant prostate cancer

CTBP1-AS

:   C terminal binding protein 1 antisense

DLK1

:   delta like homolog 1

DOT1L

:   DOT1-like histone H3K79 methyltrasferase

DTA

:   Diphtheria Toxin A

EMT

:   epithelial -mesenchymal transition

EZH2

:   enhancer of zeste homolog 2

GAS5

:   growth-arrest specific 5

GDF15

:   growth differentiation factor 15

GWAS

:   Genome Wide Association Studies

HIF-1α

:   hypoxia-inducible factor 1α

HOTAIR

:   HOX transcript antisense RNA

HOXC

:   Homeobox C

ICG

:   interchromatin granule

IGF2

:   Insulin-like growth factor 2

LOI

:   loss of imprinting

MALAT1

:   metastasis-associated lung adenocarcinoma tran-script-1

MEG3

:   maternally expressed 3

mTOR

:   mammalian target of rapamycin

NKD1

:   naked cuticle homolog 1

PCA3

:   prostate cancer gene 3

PCAT-1

:   prostate cancer associated transcript 1

PCAT29

:   prostate cancer-associated transcript 29

PcG

:   Polycomb body

PCGEM1

:   prostate cancer 2 gene expression marker 1

PRC1

:   polycomb repressive complex 1

PRC2

:   polycomb repressive complex 2

PRNCR1

:   PCa non-coding RNA 1

PYGO2

:   pygopus family PHD finger 2

RASSF1A

:   Ras-association domain family member 1A

RCC

:   Renal cell carcinoma

RIP-Seq

:   RNA immunoprecipitation and sequencing

SCHLAP1

:   second chromosome locus associated with prostate-1

SUZ12

:   suppressor of zeste 12 homolog

SWI/SNF

:   switch/sucrose non-fermenting

TCC

:   transitional cell carcinoma

TUG1

:   taurine upregulated gene 1

Xist

:   X-inactive specific transcript.
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###### 

lncRNAs involved in urologic cancer.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Name          Cancer                    Location   Source      Expression   Function                                                                                                  Clinical utility
  ------------- ------------------------- ---------- ----------- ------------ --------------------------------------------------------------------------------------------------------- ------------------------------
  3\'aHIF-1α    Kidney                    14q23.2    Tissue      ↑            Downregulates HIF-1α translation by binding to its 3\' UTR.                                               Marker for nonpapillary RCC

  H19           Bladder                   11p15.5    Tissue/\    ↑            Paternally hypomethylated; Silences IGF2 and NKD1, activates Wnt/β-catenin, promotes EMT                  Prognosis
                                                     Cell line                                                                                                                          

  H19           Kidney                    11p15.5    Tissue      ↓            Maternally methylated; Causes biallelic expression of IGF2; Precursor of miR-675                          Risk prediction

  HOTAIR        Prostate/\                12q13.13   Tissue/\    ↑            Guides PRC2 and LSD1/CoREST/REST complexes to HOXD locus for epigenetic silencing                         Prognosis
                Bladder                              Cell line                                                                                                                          

  Linc00963     Prostate                  9q34.11    Cell line   ↑            Inhibits EGFR expression; Attenuates motility and invasion; Enhances apoptosis                            Prognosis

  lincRNA-p21   Prostate                             Urine/\     ↓            suppresses expression of the genes transcriptionally regulated by p53 by binding to the hnRNP-K complex   Diagnosis
                                                     Exosome                                                                                                                            

  linc-UBC1     Bladder                   1q32.1     Tissue      ↑            Recruits PRC2 complex and regulates histone methylation of target genes                                   Prognosis

  MALAT1        Bladder/Kidney/Prostate   11q13.1    Tissue      ↑            Interacts with unmethylated Pc2; Activates growth control gene; Influences alternative splicing           Diagnosis and Prognosis

  MD-miniRNA    Prostate                  11q13.1    Plasma      ↑                                                                                                                      Diagnosis

  PCA3          Prostate                  9q21-22    Tissue/\    ↑            Modulates AR signaling                                                                                    Diagnosis
                                                     Urine                                                                                                                              

  PCAN-R1       Prostate                  1q32.1     Tissue      ↑            Inhibits cell growth and soft-agar colony formation                                                       Prognosis

  PCAN-R2       Prostate                  9q22.32    Tissue      ↑            Inhibits cell proliferation and soft-agar colony formation                                                Prognosis

  PCAT1         Prostate                  8q24.21    Tissue/\    ↑            Downregulates BRCA2; Disrupts miR-34a mediated down-regulation of cMyc                                    Prognosis
                                                     Cell                                                                                                                               

  PCAT18        Prostate                  18q11.2    Tissue      ↑            Inhibits apoptosis and migration                                                                          Prognosis

  PCAT29        Prostate                  15q23      Tissue/\    ↓            Suppresses growth and metastasis                                                                          Prognosis
                                                     Cell line                                                                                                                          

  PCGEM1        Prostate                  2q32       Tissue      ↑            Promotes cell proliferation; Delays p21 and p53 expression; Inhibits apoptosis                            Risk prediction/\
                                                                                                                                                                                        Prognosis

  PRNCR1        Prostate                  8q24       Tissue      ↑            Increases viability in the androgen-dependent LNCaP cells                                                 Risk prediction

  RASSF1-AS1    Prostate                  3p21.3     Tissue/\    ↑            Represses RASSF1A transcription via H3K27Me3                                                              Prognosis
                                                     Cell line                                                                                                                          

  RCCRT1        Kidney                               Tissue      ↑            Associates with clinicopathologic parameters                                                              Prognosis

  SCHLAP1       Prostate                  2q31.1     Tissue      ↑            Impairs SWI/SNF-mediated epigenetic regulation                                                            Prognosis

  SPRY4-IT1     Kidney                    5q31.3     Tissue      ↑            Enhances proliferation, migration, and invasion                                                           Prognosis

  TRPM2-AS      Prostate                  21q22.3    Tissue      ↑            Silences TRPM2 expression                                                                                 Prognosis Therapeutic target

  UCA1          Bladder                   19p13.12   Urine       ↑            Regulates cell cycle distribution via CREB through PI3-K dependent pathway                                Diagnosis

  XIST          Prostate                  Xq13.2     Serum       \-           Hypomethylated in PCa; Recruits PRC2 onto the Xic and initiates H3K27me3                                  Diagnosis
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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